Des-γ-carboxyprothrombin: Clinical effectiveness and biochemical importance

BioScience Trends

Volumn 2, Issue 2, 2008, Pages 53-60

  Inagaki, Yoshinori ^a   Tang, Wei ^a,b   Xu, Huanli ^a,b   Wang, Fengshan ^b   Nakata, Munehiro ^c   Sugawara, Yasuhiko ^a   Kokudo, Norihiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SHANDONG UNIVERSITY   (China)

^c TOKAI UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Cancer cell proliferation; Des carboxyprothrombin; Hepatocellular carcinoma; Tumor marker

Indexed keywords

PROTEIN PRECURSOR; PROTHROMBIN;

ANIMAL; BIOLOGICAL MODEL; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MODELS, BIOLOGICAL; PROTEIN PRECURSORS; PROTHROMBIN;

EID: 55749089424     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, followup and management of patients with hepatocellular carcinoma. Oncology 2002; 62(Suppl 1):57-63.
2. Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 2004; 127: S126-S132.
3. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12:1175-1181.
4. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003; 37:1114-1121.
5. Wang CS, Lin CL, Lee HC, Chen KY, Chiang MF, Chen HS, Lin TJ, Liao LY. Usefulness of serum des-gammacarboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol 2005; 11:6115-6119.
6. Kim do Y, Paik YH, Ahn SH, Youn YJ, Choi JW, Kim JK, Lee KS, Chon CY, Han KH. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 2007; 72:52-57.
7. Mann KG. Prothrombin. Methods Enzymol 1976; 45:123-156.
8. Suttie JW. Vitamin K-dependent carboxylase. Annu Rev Biochem 1985; 54:459-477.
9. Furie B, Furie BC. Molecular basis of vitamin K-dependent gamma-carboxylation. Blood 1990; 75:1753-1762.
10. Naraki T, Kohno N, Saito H, Fujimoto Y, Ohhira M, Morita T, Kohgo Y. gamma-Carboxyglutamic acid content of hepatocellular carcinoma-associated desgamma-carboxy prothrombin. Biochim Biophys Acta 2002; 1586:287-298.
11. Shah DV, Engelke JA, Suttie JW. Abnormal prothrombin in the plasma of rats carrying hepatic tumors. Blood 1987; 69:850-854.
12. Shah DV, Zhang P, Engelke JA, Bach AU, Suttie JW. Vitamin K-dependent carboxylase activity, prothrombin mRNA, and prothrombin production in two cultured rat hepatoma cell lines. Thromb Res 1993; 70:365-373.
13. Okuda H, Obata H, Nakanishi T, Furukawa R, Hashimoto E. Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study. J Hepatol 1987; 4:357-363.
14. Sakon M, Monden M, Gotoh M, Kobayashi K, Kanai T, Umeshita K, Endoh W, Mori T. The effects of vitamin K on the generation of des-gamma-carboxy prothrombin (PIVKA-II) in patients with hepatocellular carcinoma. Am J Gastroenterol 1991; 86:339-345.
15. Huisse MG, Leclercq M, Belghiti J, Flejou JF, Suttie JW, Bezeaud A, Stafford DW, Guillin MC. Mechanism of the abnormal vitamin K-dependent gamma-carboxylation process in human hepatocellular carcinomas. Cancer 1994; 74:1533-1541.
16. Ono M, Ohta H, Ohhira M, Sekiya C, Namiki M. Measurement of immunoreactive prothrombin, desgamma-carboxy prothrombin, and vitamin K in human liver tissues: overproduction of immunoreactive prothrombin in hepatocellular carcinoma. Am J Gastroenterol 1990; 85:1149-1154.
17. Yamagata H, Nakanishi T, Furukawa M, Okuda H, Obata H. Levels of vitamin K, immunoreactive prothrombin, des-gamma-carboxy prothrombin and gamma-glutamyl carboxylase activity in hepatocellular carcinoma tissue. J Gastroenterol Hepatol 1995; 10:8-13.
18. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS, Furie B. Des-gammacarboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310:1427-1431.
19. Fujiyama S, Morishita T, Sagara K, Sato T, Motohara K, Matsuda I. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma. Hepatogastroenterology. 1986; 33:201-205.
20. Fujiyama S, Morishita T, Hashiguchi O, Sato T. Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer 1988; 61:1621-1628.
21. Suzuki H, Akahane Y, Tanaka M, Tanikawa K, Okuda H, Saito A, Hayashi N, Saito S, Kumada H, Sekiya C, Fujiyama S, Nakano A. Clinical evaluation of PIVKA-II kit (ED-036). Kan Tan Sui 1996; 33:1069-1076.
22. Takatsu K, Nakanishi T, Watanabe K, Okuda H, Saito A, Tanaka M, Akahane Y, Hayashi K, Kumada H, Tanikawa K, Kawai T, Suzuki H. Development and performance of an assay kit for PIVKA-II (ED-038) by ECL technique. Jpn J Clin Exp Med 1996; 73:2656-2664.
23. Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998; 82:1643-1648.
24. Nomura F, Ishijima M, Kuwa K, Tanaka N, Nakai T, Ohnishi K. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 1999; 94:650-654.
25. Sassa T, Kumada T, Nakano S, Uematsu T. Clinical utility of simultaneous measurement of serum highsensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1999; 11:1387-1392.
26. Blanchard RA, Furie BC, Jorgensen M, Kruger SF, Furie B. Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med 1981; 305:242-248.
27. Owens J, Lewis RM, Cantor A, Furie BC, Furie B. Monoclonal antibodies against human abnormal (desgamma-carboxy)prothrombin specific for the calciumfree conformer of prothrombin. J Biol Chem 1984; 259:13800-13805.
28. Grosley BM, Hirschauer C, Chambrette B, Bezeaud A, Amiral J. Specific measurement of hypocarboxylated prothrombin in plasma or serum and application to the diagnosis of hepatocellular carcinoma. J Lab Clin Med 1996; 127:553-564.
29. Motohara K, Kuroki Y, Kan H, Endo F, Matsuda I. Detection of vitamin K deficiency by use of an enzymelinked immunosorbent assay for circulating abnormal prothrombin. Pediatr Res 1985; 19:354-357.
30. Nagaoka S, Yatsuhashi H, Hamada H, Yano K, Matsumoto T, Daikoku M, Arisawa K, Ishibashi H, Koga M, Sata M, Yano M. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer 2003; 98:2671-2677.
31. Imamura H, Matsuyama Y, Miyagawa Y, Ishida K, Shimada R, Miyagawa S, Makuuchi M, Kawasaki S. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg 1999; 86:1032-1038.
32. Hamamura K, Shiratori Y, Shiina S, Imamura M, Obi S, Sato S, Yoshida H, Omata M. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000; 88:1557-1564.
33. Suehiro T, Matsumata T, Itasaka H, Taketomi A, Yamamoto K, Sugimachi K. Des-gamma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma. Surgery 1995; 117:682-691.
34. Sakon M, Monden M, Gotoh M, Kanai T, Umeshita K, Nakano Y, Mori T, Sakurai M, Wakasa K. Relationship between pathologic prognostic factors and abnormal levels of des-gamma-carboxy prothrombin and alphafetoprotein in hepatocellular carcinoma. Am J Surg 1992; 163:251-256.
35. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, Yoshida H, Shiina S, Omata M. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91:561-569.
36. Tang W, Miki K, Kokudo N, Sugawara Y, Imamura H, Minagawa M, Yuan LW, Ohnishi S, Makuuchi M. Desgamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma. Int J Oncol 2003; 22:969-975.
37. Miyaaki H, Nakashima O, Kurogi M, Eguchi K, Kojiro M. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol 2007; 42:962-968.
38. Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A, Maeda T. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alphafetoprotein. Cancer 1994; 73:2464-2471.
39. Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, Toshikuni N, Tanaka H, Miyake Y, Matsumoto E, Shiratori Y. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006; 101:2038-2043.
40. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark 2007; 3:79-87.
41. Shimauchi Y, Tanaka M, Kuromatsu R, Ogata R, Tateishi Y, Itano S, Ono N, Yutani S, Nagamatsu H, Matsugaki S, Yamasaki S, Tanikawa K, Sata M. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep 2000; 7:249-256.
42. Ikoma J, Kaito M, Ishihara T, Nakagawa N, Kamei A, Fujita N, Iwasa M, Tamaki S, Watanabe S, Adachi Y. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum desgamma-carboxy prothrombin: a prospective study. Hepatogastroenterology 2002; 49:235-238.
43. Tamano M, Sugaya H, Oguma M, Iijima M, Yoneda M, Murohisa T, Kojima K, Kuniyoshi T, Majima Y, Hashimoto T, Terano A. Serum and tissue PIVKA-II expression reflect the biological malignant potential of small hepatocellular carcinoma. Hepatol Res 2002; 22:261-269.
44. Yuan LW, Tang W, Kokudo N, Sugawara Y, Karako H, Hasegawa K, Aoki T, Kyoden Y, Deli G, Li YG, Makuuchi M. Measurement of des-gamma-carboxy prothrombin levels in cancer and non-cancer tissue in patients with hepatocellular carcinoma. Oncol Rep 2004; 12:269-273.
45. Tang W, Kokudo N, Sugawara Y, Guo Q, Imamura H, Sano K, Karako H, Qu X, Nakata M, Makuuchi M. Desgamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: association with survival of patients with resectable hepatocellular carcinoma. Oncol Rep 2005; 13:25-30.
46. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342:440-443.
47. Suzuki M, Shiraha H, Fujikawa T, Takaoka N, Ueda N, Nakanishi Y, Koike K, Takaki A, Shiratori Y. Desgamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem 2005; 280:6409-6415.
48. Fujikawa T, Shiraha H, Ueda N, Takaoka N, Nakanishi Y, Matsuo N, Tanaka S, Nishina S, Suzuki M, Takaki A, Sakaguchi K, Shiratori Y. Des-gammacarboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J Biol Chem 2007; 282:8741-8748.
49. Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT. Biology of hepatocellular carcinoma. Ann Surg Oncol 2008; 15:962-971.
50. Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, Fan ST, Wong J. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002; 20:1775-1785.